WALTHAM, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted […]
Fiscal Year 2020Revenue increased 10% year-over-year to $405.1 millionNet income from continuing operations increased to $7.8 millionAdjusted EBITDA increased 49% […]